Summit Partners Public Asset Management’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$145M Buy
967,697
+104,782
+12% +$11.4M 2.55% 3
2026
Q1
$79.7M Buy
862,915
+10,957
+1% +$1.1M 2.14% 10
2025
Q4
$87M Buy
851,958
+741,958
+675% +$66.4M 1.81% 17
2025
Q3
$6.87M Buy
+110,000
New +$5.98M 0.14% 114
2021
Q1
Sell
-79,532
Closed -$10.3M 104
2020
Q4
$10.3M Sell
79,532
-285
-0.4% -$32.8K 0.46% 63
2020
Q3
$8.92M Sell
79,817
-168,896
-68% -$15.5M 0.45% 62
2020
Q2
$20.2M Buy
248,713
+56,300
+29% +$4.54M 1.21% 26
2020
Q1
$13.4M Sell
192,413
-87,587
-31% -$6.72M 1.1% 31
2019
Q4
$21.9M Buy
280,000
+109,931
+65% +$7.92M 2.07% 15
2019
Q3
$10.9M Buy
170,069
+100,071
+143% +$8.82M 1.07% 38
2019
Q2
$6.04M Buy
+69,998
New +$5.35M 0.6% 64

Other funds holding GH

Summit Partners Public Asset Management's GH Position: Q2 2026 in Review

Summit Partners Public Asset Management increased its Guardant Health (GH) stake by 12% in Q2 2026, buying an estimated $11.4M and bringing the position to 967,697 shares worth $145M. The position accounts for 2.55% of the portfolio, ranked #3.

Summit Partners Public Asset Management first reported a position in GH in Q2 2019 and has held it in 11 quarters since. 600 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Summit Partners Public Asset Management held 967,697 shares of Guardant Health worth $145M as of Q2 2026.
  • Summit Partners Public Asset Management bought 104,782 Guardant Health shares in Q2 2026, an estimated $11.4M.
  • Guardant Health made up 2.55% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #3 holding.
  • Summit Partners Public Asset Management first reported a position in Guardant Health in Q2 2019 and has held it in 11 quarters since.
  • 600 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.